Philip N. Hawkins
YOU?
Author Swipe
View article: Artificial intelligence‐based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis
Artificial intelligence‐based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis Open
Aims In transthyretin amyloid cardiomyopathy ( ATTR ‐ CM ), reduced stroke volume ( SV ) portends a poor prognosis. Artificial intelligence ( AI ) enables rapid, standardized assessment of left ventricular outflow tract velocity‐time integ…
View article: Transthyretin amyloid cardiomyopathy: from cause to novel treatments
Transthyretin amyloid cardiomyopathy: from cause to novel treatments Open
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disorder marked by amyloid deposition in the heart, ultimately impairing cardiac function. Recent treatment advances have paralleled an evolving understanding of ATTR-CM patho…
View article: Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy
Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy Open
Our study indicates a poor correlation between reduction in 99mTc-DPD uptake at follow-up and numerous established biomarkers of ATTR-CM treatment response. Changes in DPD uptake in ATTR-CM patients receiving DMT should be inter…
View article: A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis
A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis Open
Not available.
View article: Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis
Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis Open
Renal prognosis in light-chain amyloidosis (AL) is determined by categorizing patients into three renal stages at diagnosis and assessing Renal Response or Renal Progression following chemotherapy after 6 months. We evaluated, in a test (N…
View article: Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis
Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis Open
Frailty is common in ATTR-CA and is independently linked to increased mortality risk. Incorporating frailty assessment alongside traditional markers enhances prognostication across genotypes and disease severities, particularly for short-t…
View article: Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis
Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis Open
Summary Systemic light chain (AL) amyloidosis is an incurable disorder caused by extra‐cellular deposition of light‐chain aggregates in critical organs. An immunomodulatory agent‐based quadruplet including anti‐CD38 therapy has not been in…
View article: Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid Infiltration
Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid Infiltration Open
Importance Patients with transthyretin (ATTR) cardiac amyloid infiltration are increasingly diagnosed at earlier disease stages with no heart failure (HF) symptoms and a wide range of cardiac amyloid infiltration. Objective To characterize…
View article: Ethnicity in systemic AL amyloidosis may impact risk stratification
Ethnicity in systemic AL amyloidosis may impact risk stratification Open
Not available.
View article: Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy
Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy Open
Importance Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cardiomyopathy that commonly presents with concomitant chronic kidney disease. Chronic kidney dysfunction is associated with worse outcomes, but the prognostic valu…
View article: Microvascular obstruction in cardiac amyloidosis
Microvascular obstruction in cardiac amyloidosis Open
Microvascular obstruction is common in CA and is related to markers of amyloid infiltration. MVO is associated with an increased risk of mortality in AL-CA, but not in ATTR-CA. This reflects the intrinsic differences in disease biology bet…
View article: Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis Open
Importance Cardiac amyloid infiltration is the key determinant of survival in systemic light-chain (AL) amyloidosis. Current guidelines recommend early switching therapy in patients with a nonoptimal or suboptimal response regardless of th…
View article: Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis
Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis Open
Aims Transthyretin cardiac amyloidosis (ATTR‐CA) is stratified into prognostic categories using the National Amyloidosis Centre (NAC) staging system. The aims of this study were to further expand the existing NAC staging system to incorpor…
View article: Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (<scp>DVD</scp>) in relapsed/refractory light chain amyloidosis (<scp>AL</scp>) after initial Bortezomib‐based regime
Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (<span>DVD</span>) in relapsed/refractory light chain amyloidosis (<span>AL</span>) after initial Bortezomib‐based regime Open
Summary Bortezomib is regularly used as frontline therapy for systemic AL amyloidosis. We assess the efficacy of second‐line daratumumab‐bortezomib‐dexamethasone (DVD) in AL amyloidosis in bortezomib‐exposed patients. A total of 116 patien…
View article: SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy Open
View article: Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis
Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis Open
The baseline 6MWT distance can refine risk stratification beyond traditional prognosticators. A worsening 6MWT distance can stratify disease progression and, when combined with established markers, identifies patients at the highest risk o…
View article: Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis
Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis Open
NT-proBNP progression and ODI are frequent and consistently associated with an increased risk of mortality. Combining both variables produces a simple, universally applicable model that detects disease progression in ATTR-CA.
View article: Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker
Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker Open
Background. The cardiomyopathic and neuropathic phenotype of hereditary transthyretin amyloidosis are well recognized. Cardiovascular autonomic dysfunction is less systematically and objectively assessed. Methods. Autonomic and clinical fe…
View article: Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis
Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis Open
Importance Cardiopulmonary exercise testing (CPET) has an established role in the assessment of patients with heart failure. However, data are lacking in patients with transthyretin (ATTR) amyloidosis. Objective To use CPET to characterize…
View article: 5 Cardiovascular magnetic resonance (CMR) in transthyretin amyloid cardiomyopathy – a study of natural history and treatment repsonse
5 Cardiovascular magnetic resonance (CMR) in transthyretin amyloid cardiomyopathy – a study of natural history and treatment repsonse Open
Introduction Cardiovascular magnetic resonance (CMR) and extracellular volume (ECV) mapping can quantify amyloid burden in patients with cardiac amyloidosis. At present, there is a paucity of data on tracking changes in amyloid deposition …
View article: Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy
Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy Open
BACKGROUND: The extent of myocardial bone tracer uptake with technetium pyrophosphate, hydroxymethylene diphosphonate, and 3,3-diphosphono-1,2-propanodicarboxylate in transthyretin amyloid cardiomyopathy (ATTR-CM) might reflect cardiac amy…
View article: Multiorgan Dysfunction and Associated Prognosis in Transthyretin Cardiac Amyloidosis
Multiorgan Dysfunction and Associated Prognosis in Transthyretin Cardiac Amyloidosis Open
Background Transthyretin cardiac amyloidosis (ATTR‐CA) is a progressive and ultimately fatal cardiomyopathy. Biomarkers reflecting multiorgan dysfunction are of increasing importance in patients with heart failure; however, their significa…
View article: Myocardial perfusion in cardiac amyloidosis
Myocardial perfusion in cardiac amyloidosis Open
Aims Cardiac involvement is the main driver of clinical outcomes in systemic amyloidosis and preliminary studies support the hypothesis that myocardial ischaemia contributes to cellular damage. The aims of this study were to assess the pre…
View article: Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients
Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients Open
Not available.
View article: Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy
Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy Open
View article: Cardiovascular Magnetic Resonance (CMR) in Transthyretin Amyloid Cardiomyopathy – a Study of Natural History of Treatment Response
Cardiovascular Magnetic Resonance (CMR) in Transthyretin Amyloid Cardiomyopathy – a Study of Natural History of Treatment Response Open
View article: Albuminuria in transthyretin cardiac amyloidosis: Prevalence, progression and prognostic importance
Albuminuria in transthyretin cardiac amyloidosis: Prevalence, progression and prognostic importance Open
Aims Transthyretin cardiac amyloidosis (ATTR‐CA) is an infiltrative cardiomyopathy that commonly presents with concomitant chronic kidney disease. Albuminuria is common in heart failure and associated with worse outcomes, but its prevalenc…
View article: Deep phenotyping of p.(<scp>V142I</scp>)‐associated variant transthyretin amyloid cardiomyopathy: Distinct from wild‐type transthyretin amyloidosis?
Deep phenotyping of p.(<span>V142I</span>)‐associated variant transthyretin amyloid cardiomyopathy: Distinct from wild‐type transthyretin amyloidosis? Open
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasingly recognized cause of heart failure. A total of 3–4% of individuals of African descent carry a TTR gene mutation encoding the p.(V142I) variant, a powerful risk factor fo…
View article: The clinical significance of transthyretin gene variant homozygosity in variant ATTR-CM
The clinical significance of transthyretin gene variant homozygosity in variant ATTR-CM Open
Background Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a progressive condition characterised by the infiltration of the myocardial extracellular space resulting in progressive heart failure and mortality. Owing to advances in imaging…
View article: Tracking Treatment Response in Cardiac Light-Chain Amyloidosis With Native T1 Mapping
Tracking Treatment Response in Cardiac Light-Chain Amyloidosis With Native T1 Mapping Open
Importance Cardiac magnetic resonance (CMR) imaging–derived extracellular volume (ECV) mapping, generated from precontrast and postcontrast T1, accurately determines treatment response in cardiac light-chain amyloidosis. Native T1 mapping,…